Catalyst Pharmaceutical Partners (CPRX)

[$$$eeker]

$CPRX

8:03 am Catalyst Pharma reports 'Positive' cardiac safety results of its Phase 3 product, Firdapse tablets; the study met the pre-specified primary endpoint (CPRX) : Co announced positive results from a study jointly funded with, and conducted by BioMarin Pharma (BMRN) to assess the cardiac safety of Firdapse tablets (amifampridine also known as 3,4-DAP). Firdapse is approved in the E.U., where it is marketed by BioMarin. Firdapse is also currently in Phase 3 development in the U.S. for Lambert-Eaton Myasthenic Syndrome (:LEMS) by Catalyst.
http://yhoo.it/1hvg7Ak